Similar anti-neoplastic effects have been seen following in vitro and in vivo treatment of CRC cells with SF1126, a BRD4 and phosphatidylinositol 3-kinase dual inhibitor, which activates p38 signaling thus inducing cytotoxicity and apoptosis (Qin et al., 2019), a combined treatment with AZD5153, a BRD4 inhibitor, and the PARP inhibitor BMN673 (Zhang et al., 2019) or the nontoxic dietary supplement, docosahexaenoic acid, and JQ1 (Ding et al., 2020). The gene discussed is BRD4; the disease is colorectal carcinoma.